-transparent.png){kind=logo}
Milrinone is an inotropic agent for short-term intravenous use in the management of congestive heart failure. The purpose of this article is to question the previously reported lack of transplacental transfer of milrinone. Loading and continuous intravenous doses, considered to be therapeutic in humans, were administered to four near-term baboons. Transplacental passage was documented, with a maternal/fetal serum ratio of approximately 4:1 found during the 3 hours of infusion.
Related Publications
B D Atkinson, and
J I Fishburne, and
K A Hales, and
G H Levy, and
W F Rayburn
September 2001,
NeuroImage,
B D Atkinson, and
J I Fishburne, and
K A Hales, and
G H Levy, and
W F Rayburn
May 2006,
Vaccine,
B D Atkinson, and
J I Fishburne, and
K A Hales, and
G H Levy, and
W F Rayburn
January 2004,
Methods in enzymology,
B D Atkinson, and
J I Fishburne, and
K A Hales, and
G H Levy, and
W F Rayburn
January 2014,
Advances in experimental medicine and biology,
B D Atkinson, and
J I Fishburne, and
K A Hales, and
G H Levy, and
W F Rayburn
January 2004,
Gynecologic and obstetric investigation,
B D Atkinson, and
J I Fishburne, and
K A Hales, and
G H Levy, and
W F Rayburn
November 1999,
Experimental neurology,
B D Atkinson, and
J I Fishburne, and
K A Hales, and
G H Levy, and
W F Rayburn
February 2019,
BioTechniques,
B D Atkinson, and
J I Fishburne, and
K A Hales, and
G H Levy, and
W F Rayburn
July 1998,
Pediatric research,
B D Atkinson, and
J I Fishburne, and
K A Hales, and
G H Levy, and
W F Rayburn
December 2021,
Journal of developmental origins of health and disease,
B D Atkinson, and
J I Fishburne, and
K A Hales, and
G H Levy, and
W F Rayburn
January 2003,
Obesity research,
